We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 25, 2017

Dasatinib With Trastuzumab and Paclitaxel Feasible in First Line for HER2-Overexpressing Advanced Breast Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase I Study of the SRC Kinase Inhibitor Dasatinib With Trastuzumab and Paclitaxel as First Line Therapy for Patients With HER2-Overexpressing Advanced Breast Cancer. GEICAM/2010-04 Study
Oncotarget 2017 Apr 14;[EPub Ahead of Print], A Ocana, M Gil-Martin, M Martín, F Rojo, S Antolín, Á Guerrero, JM Trigo, M Muñoz, A Pandiella, NG Diego, S Bezares, R Caballero, E Carrasco, A Urruticoechea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading